Targeted Therapy
Approved for: NSCLC
Biomarker: ALK, ROS1
Crizotinib (Xalkori) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive or ROS1 positive and has metastasized (spread to other parts of the body).
FDA-Approved Lung Cancer Treatments
Crizotinib (Xalkori)
I want to give in honor of...
name or relation
Donation Amount
other amount